Suppr超能文献

移植肾后预测 HLA 细胞毒性 T 细胞表位靶点与 T 细胞介导排斥反应的关系。

Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.

机构信息

KU Leuven, Department of Microbiology, Immunology and Transplantation, KU Leuven University, Leuven, Belgium; Histocompatibility and Immunogenetics Laboratory (HILA), Belgian Red Cross-Flanders, Mechelen, Belgium.

KU Leuven, Department of Microbiology, Immunology and Transplantation, KU Leuven University, Leuven, Belgium.

出版信息

Am J Kidney Dis. 2022 Dec;80(6):718-729.e1. doi: 10.1053/j.ajkd.2022.04.009. Epub 2022 Jun 9.

Abstract

RATIONALE & OBJECTIVE: The relationship between human leukocyte antigen (HLA) molecular mismatches and T-cell-mediated rejection (TCMR) is unknown. We investigated the associations between the different donor HLA-derived T-cell targets and the occurrence of TCMR and borderline histologic changes suggestive of TCMR after kidney transplantation.

STUDY DESIGN

Retrospective cohort study.

SETTING & PARTICIPANTS: All kidney transplant recipients at a single center between 2004 and 2013 with available biopsy data and a DNA sample for high-resolution HLA donor/recipient typing (N = 893).

EXPOSURE

Scores calculated by the HLA matching algorithm PIRCHE-II and HLA eplet mismatches.

OUTCOME

TCMR, borderline changes suggestive of TCMR, and allograft failure.

ANALYTICAL APPROACH

Multivariable cause-specific hazards models were fit to characterize the association between HLA epitopes targets and study outcomes.

RESULTS

We found 277 patients developed TCMR, and 134 developed only borderline changes suggestive of TCMR on at least 1 biopsy. In multivariable analyses, only the PIRCHE-II scores for HLA-DRB1 and HLA-DQB1 were independently associated with the occurrence of TCMR and with allograft failure; this was not the case for HLA class I molecules. If restricted to rejection episodes within the first 3 months after transplantation, only the T-cell epitope targets originating from the donor's HLA-DRB1 and HLA-DQB1, but not class I molecules, were associated with the early acute TCMR. Also, the median PIRCHE-II score for HLA class II was statistically different between the patients with TCMR compared to the patients without TCMR (129 [IQR, 60-240] vs 201 [IQR, 96-298], respectively; P < 0.0001). These differences were not observed for class I PIRCHE-II scores.

LIMITATIONS

Observational clinical data and residual confounding.

CONCLUSIONS

In the absence of HLA-DSA, HLA class II but not class I mismatches are associated with early episodes of acute TCMR and allograft failure. This suggests that current immunosuppressive therapies are largely able to abort the most deleterious HLA class I-directed alloimmune processes; however, alloresponses against HLA-DRB1 and HLA-DQB1 molecular mismatches remain insufficiently suppressed.

PLAIN-LANGUAGE SUMMARY: Genetic differences in the human leukocyte antigen (HLA) complex between kidney transplant donors and recipients play a central role in T-cell-mediated rejection (TCMR), which can lead to failure of the transplanted kidney. Evaluating this genetic disparity (mismatch) in the HLA complex at the molecular (epitope) level could contribute to better prediction of the immune response to the donor organ posttransplantation. We investigated the associations of the different donor HLA-derived T-cell epitope targets and scores obtained from virtual crossmatch algorithms with the occurrence of TCMR, borderline TCMR, and graft failure after kidney transplantation after taking into account the influence of donor-specific anti-HLA antibodies. This study illustrates the greater importance of the molecular mismatches in class II molecules compared to class I HLA molecules.

摘要

背景与目的

人类白细胞抗原(HLA)分子错配与 T 细胞介导的排斥反应(TCMR)之间的关系尚不清楚。我们研究了不同供体 HLA 衍生 T 细胞靶标与肾移植后 TCMR 及提示 TCMR 的边缘组织学变化的发生之间的相关性。

研究设计

回顾性队列研究。

研究地点和参与者

2004 年至 2013 年间在一家单中心接受肾移植的所有患者,这些患者均具有可获得的活检数据和用于高分辨率 HLA 供体/受者分型的 DNA 样本(N=893)。

暴露

通过 HLA 匹配算法 PIRCHE-II 和 HLA 表位错配计算的评分。

结局

TCMR、提示 TCMR 的边缘改变和移植物失功。

分析方法

采用多变量因果风险模型来描述 HLA 表位靶标与研究结局之间的关联。

结果

我们发现 277 例患者发生 TCMR,134 例患者至少有 1 次活检出现仅提示 TCMR 的边缘改变。多变量分析显示,只有 HLA-DRB1 和 HLA-DQB1 的 PIRCHE-II 评分与 TCMR 的发生和移植物失功相关,而 HLA Ⅰ类分子则不然。如果仅将排斥反应限于移植后 3 个月内,仅来自供体 HLA-DRB1 和 HLA-DQB1 的 T 细胞表位靶标与早期急性 TCMR 相关,而不是 HLA Ⅰ类分子。此外,与无 TCMR 的患者相比,发生 TCMR 的患者的 HLA Ⅱ类 PIRCHE-II 评分中位数存在统计学差异(129[IQR,60-240]与 201[IQR,96-298];P<0.0001)。而 HLA Ⅰ类 PIRCHE-II 评分则没有观察到这种差异。

局限性

观察性临床数据和残余混杂因素。

结论

在没有 HLA-DSA 的情况下,HLA Ⅱ类而非 HLA Ⅰ类错配与早期急性 TCMR 和移植物失功相关。这表明目前的免疫抑制治疗在很大程度上能够阻止最具危害性的 HLA Ⅰ类同种免疫过程;然而,针对 HLA-DRB1 和 HLA-DQB1 分子错配的同种反应仍然没有得到充分抑制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验